Skip to content

Screening of Healthy Volunteers: Evaluation and Optimization of a Key Process for Clinical Trials Phase 0/I

Screening of Healthy Volunteers: Evaluation and Optimization of a Key Process for Clinical Trials Phase 0/I

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
DRKS
Registry ID
DRKS00039582
Enrollment
150
Registered
2026-03-16
Start date
2023-05-20
Completion date
Unknown
Last updated
2026-03-30

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Study with healthy volunteers

Interventions

Group 1: Part 1: Retrospective data analysis of screening tests from previous studies Group 2: Part 2: Prospective data collection through interviews and questionnaires.

Sponsors

Universitätsklinikum Heidelberg
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to No maximum

Inclusion criteria

Inclusion criteria: Part 1: - Screening examination as a healthy volunteer within an approved Phase 0 or Phase I clinical trial conducted under the German Medicinal Products Act (AMG) between 2012 and 2022. Part 2: - Ability to understand the study information and willingness to provide written informed consent for voluntary study participation. - Current or = 24-month prior participation in a clinical trial involving healthy volunteers conducted under the German Medicinal Products Act (AMG).

Exclusion criteria

Exclusion criteria: Part 1: None. Part 2: Inability to communicate with the study physician or to understand the study procedures.

Design outcomes

Primary

MeasureTime frame
Part 1: - Screening success rate - Identification of reasons for screen failure - Classification of screen failure reasons and evaluation by frequency Part 2: Identification of key topics in the screening process using semi-structured interviews, followed by the development of a questionnaire. Descriptive analysis of the questionnaire, particularly insights regarding: - Participants' expectations regarding the informed consent discussion - Decision-making processes and motivations for participation in the study - Participants’ risk perception of studies in general and study-related procedures - Quality of the informed consent discussion

Secondary

MeasureTime frame
Part 1: - Comparison of screening success rates and reasons for screen failure across studies Part 2: - Analysis of subgroups, correlations, and influencing factors based on sociodemographic data and other responses from the data collection.

Countries

Germany

Contacts

Public ContactAntje Blank

Universitätsklinikum Heidelberg

klips@med.uni-heidelberg.de+49 6221 / 56-38745

Outcome results

None listed

Source: DRKS (via WHO ICTRP) · Data processed: Apr 4, 2026